What we know about aducanumab, the new drug to treat Alzheimer’s disease

Earlier this week, the federal Food and Drug Administration (FDA) approved the use of the drug aducanumab to treat Alzheimer’s disease—making it the first new drug in nearly 20-years to treat the disease. Aducanumab is the first of a new generation of drugs that target the underlying damage in the brain. Anton Porsteinsson, M.D., is …

Cancer and exercise during a pandemic

What options do cancer survivors have during a pandemic when there are limited in-person training options and reduced access to exercise facilities? With National Cancer Survivors Day on June 6, Marina Mourtzakis, a Kinesiology professor who leads Waterloo’s Center for Community, Clinical and Applied Research Excellence, examines how to exercise safely as a cancer survivor …

New antibody therapy may reverse diabetic retinopathy and other eye conditions

The life-saving diabetic medication insulin, developed at the University of Toronto 100 years ago, was the first biologic therapy—a protein to treat disease. A century later, a new biologic therapy also developed by researchers at U of T has potential to reverse a common complication of diabetes.